Cellectis BPA estimée Q/Q
Quel est le BPA estimée Q/Q de Cellectis?
Le BPA estimée Q/Q de Cellectis est -45.12%
Quelle est la définition de BPA estimée Q/Q?
Le taux de croissance prospectif du BPA trimestriel, d'une année à l'autre , correspond à l'augmentation estimée du BPA d'une entreprise pour le prochain trimestre par rapport à la performance d'un trimestre précédent.
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
BPA estimée Q/Q des entreprises dans Health Care secteur sur NASDAQ par rapport à Cellectis
Que fait Cellectis?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Entreprises avec bpa estimée q/q similaire à Cellectis
- Banco Macro S.A a BPA estimée Q/Q de -45.38%
- American International Inc a BPA estimée Q/Q de -45.36%
- Western Union a BPA estimée Q/Q de -45.31%
- Passage Bio Inc a BPA estimée Q/Q de -45.26%
- Teradyne a BPA estimée Q/Q de -45.26%
- Avanti Feeds a BPA estimée Q/Q de -45.24%
- Cellectis a BPA estimée Q/Q de -45.12%
- Companhia Siderurgica Nacional a BPA estimée Q/Q de -45.00%
- Copperleaf Technologies a BPA estimée Q/Q de -45.00%
- Unity Biotechnology Inc a BPA estimée Q/Q de -45.00%
- Nano Dimension Ltd a BPA estimée Q/Q de -45.00%
- PLx Pharma a BPA estimée Q/Q de -45.00%
- BXP a BPA estimée Q/Q de -44.92%